Delcath Systems, Inc. (DCTH)

Delcath Systems Reports Second Quarter 2022 Results and Provides Business Update

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2022.

• 
  STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y

  Business Wire
• 
  Euroseas Ltd. Reports Results for the Six-Month Period and Quarter Ended June 30, 2022

  GlobeNewswire

Results of a Multicenter Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced the publication of a retrospective analysis of patients who underwent a percutaneous hepatic perfusion procedure (PHP) with CHEMOSAT® at three European centers, one in the Netherlands and two in Germany, between February 2014 and December 2019. The study involved 101 patients who completed a minimum of one PHP procedure for the treatment of u

Delcath Systems to Host Second Quarter 2022 Results

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 8, 2022, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2022.